A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma

Michael J Dennis,Assuntina G Sacco, Yuchen Qi,Julie Bykowski,Emily Pittman,Ruifeng Chen,Karen Messer,Ezra E W Cohen,Kathryn A Gold

Oral Oncology（2022）

引用 3|浏览8

暂无评分

摘要

•Palbociclib, avelumab, and cetuximab was well tolerated in R/M HNSCC.•No unexpected toxicities were observed.•Promising response rates were seen (ORR 42%)

查看译文

关键词

Palbociclib,Cetuximab,Avelumab,Head and neck cancer,Squamous cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要